Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
A developmental purification system for Antibody-Drug-Conjugates will be launched by ADC Biotechnology (ADBC), a spin off from Reaxa, which promises reduced manufacturing costs for “magic bullet” cancer drugs.
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
Cell Biosciences plans to gain ground in the protein-based drugs market by acquiring Convergent Bioscience at the end of October for a cash sum of $12m (€8.6m.)
SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
SoluBest and Dr Reddy’s Laboratories are joining forces to develop a proprietary formulation of one of SoluBest’s pipeline compounds using its Solumer platform.
China leads the field in 'potential future' API suppliers, positioning it to become a dominant force as these companies develop, Thomson Reuters said at CPhI 2010.
Galapagos’ acquisition, Argenta, has signed up to a $46m cancer drug discovery service deal with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.
Belgium-based biopharmaceutical company, ThromboGenics, has signed a ten-year supply agreement with MSD Biologics, to produce microplasmin for the treatment of retinal disorders.
RXi Pharmaceuticals and EyeGate Pharma will unite to develop non-invasive, needle-free ocular delivery of RNAi therapeutics using the EyeGate II system for the treatment of retinal disorders.
Anglo-German company Evotec is joining forces with Almirall to identify small molecule modulators of an ion channel target involved in respiratory diseases.
Sheffield Bio-Science takes on responsibility for global sales, distribution and development of Girus Life Sciences’ chemically defined Regocel supplements.
TetraLogic Pharmaceuticals receives $5m (€3.7m) investment from Pfizer Ventures, helping fund clinical development of a drug that mimics naturally forming proteins, promoting cell death.
Reengineering erythropoietin (EPO) as an immunoglobulin G (IgG) fusion protein enables penetration of the blood-brain barrier (BBB) in mice, according to researchers.
DSM’s microbial fermentation CMO business unit and UK-based biopharmaceutical company, PolyTherics, have formed an agreement to develop and manufacture PolyTherics’ lead ‘biobetter’ product, HiPEG IFN a-2a.
Life Technologies has concluded license agreements, providing rights to its proprietary Chinese hamster ovary (CHO) cell lines for production of recombinant proteins used as therapeutic agents and vaccines.
In an exclusive Q&A Mark Rohlfing, Almac’s director of Quality, updates Outsourcing-pharma on the firm’s new North American HQ, growth plans and US recruitment drive.
Pall has ended fiscal 2010 with strong set of sales after recovering pharmaceutical industry demand for bioproduction tech maintained its momentum in Q4
Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.
Living Image Multi-Modality Software Module and Mouse Imaging shuttle will widen the understanding of animal biology in preclinical research, say Caliper Life Sciences.
Global biopharmaceutical company, Bristol-Myers Squibb will buy ZymoGenetics for $885m to become owner of a hepatitis C drug the companies are jointly developing.
The life sciences company, ForteBio, has launched its Dip and Read Protein G biosensor, designed for the fast-track analysis of specific biomolecular interactions of various types of the antibody molecule, mammalian immunoglobulin.
Aspect Magnetic Technologies claim its new compact M2 magnetic resonance imaging (MRI) systems “help preclinical researchers expand the horizons for completely new ideas and discovery.”
Bio Nano Consulting (BNC) launches new fluorescent tag-free technique that it says can help evaluate protein stability and ligand binding in drug discovery.
